News

Poor accrual halts one in five cancer clinical trials


 

AT THE GENITOURINARY CANCERS SYMPOSIUM

Trials were more likely to fail completion if they were funded by industry as compared with the federal government (hazard ratio, 1.97), were phase II as compared with phase III (HR, 1.29), or were single center as compared with multicenter (HR, 1.93).

On the other hand, trials were less likely to fail completion if they were conducted solely outside the United States (HR, 0.65) or both in and outside the United States (HR, 0.67), as compared with solely in the United States.

Dr. Galsky disclosed no relevant conflicts of interest.

Pages

Recommended Reading

FDA advisory panel decides tivozanib falls short for advanced renal cell carcinoma
MDedge Surgery
Forecast warns of urologist shortage
MDedge Surgery
FDA approves radiotherapy for metastatic prostate cancer
MDedge Surgery
Postop surveillance sufficient for stage I testicular cancer
MDedge Surgery
Consequences of not screening for prostate cancer prove dire
MDedge Surgery
New test beats PSA in predicting significant prostate Ca
MDedge Surgery
Prostatectomy follow-up guidelines released
MDedge Surgery
Prolaris test eyed as predictor of prostate cancer outcomes
MDedge Surgery
Prostate cancer stage has declined more than Gleason score
MDedge Surgery
ASTRO outlines five radiation oncology practices that should be curtailed
MDedge Surgery